progress
immuneassoci
injuri
hallmark
sever
acut
respiratori
syndrom
sar
viral
evas
innat
immun
hypercytokinemia
system
immunopatholog
sar
coronaviru
sar
cov
infect
host
suggest
possibl
mechan
caus
sever
patholog
morbid
sar
patient
molecular
cellular
basi
sar
cov
impact
host
immun
system
result
sever
sar
howev
elucid
variabl
clinic
cours
sar
may
result
complex
program
host
respons
infecti
agent
therefor
systemat
analysi
innat
adapt
immun
respons
sar
cov
imper
build
complet
immunolog
model
possibl
host
immun
inflammatori
respons
ill
review
recent
advanc
sar
immunopathogenesi
research
present
summari
find
regard
host
respons
sar
patient
contend
dysregul
type
ii
interferon
ifn
respons
sar
may
culmin
failur
switch
hyperinn
immun
protect
adapt
immun
respons
human
host
mj
cameron
bermejo
peduva
jf
bermejomartin
adanesh
uhnresutorontoca
danesh
mmuller
mtsinaionca
mp
muller
dkelvin
uhnresutorontoca
dj
kelvin
sever
acut
respiratori
syndrom
sar
emerg
late
guangdong
provinc
china
spread
worldwid
countri
midsumm
lau
peiri
epidem
end
novel
coronaviru
caus
sar
sar
cov
infect
person
around
world
kill
nearli
contract
diseas
inflict
great
socioeconom
strain
likelihood
anoth
sar
outbreak
uncertain
sever
sar
compar
human
coronavir
infect
mandat
continu
research
pathogenesi
sar
cov
infect
moreov
emerg
new
global
health
threat
avian
influenza
refocus
attent
deriv
better
understand
highli
pathogen
virus
caus
sever
immunopatholog
human
insight
sar
cov
may
aid
treatment
individu
infect
emerg
virus
mandavilli
sar
cov
caus
spectrum
diseas
rang
flulik
symptom
pneumonia
acut
respiratori
distress
syndrom
ard
ding
et
al
farca
et
al
hwang
et
al
lew
et
al
saltotellez
et
al
molecular
cellular
basi
sar
cov
impact
host
immun
system
result
sever
morbid
mortal
well
understood
point
believ
variabl
pathogenesi
sever
sar
may
result
complex
program
host
respons
infecti
agent
therefor
analysi
innat
adapt
immun
respons
sar
cov
whole
host
level
imper
build
complet
model
possibl
immun
inflammatori
respons
clinic
evolut
sar
review
recent
advanc
sar
immunopathogenesi
research
present
overview
find
regard
host
immun
respons
sar
patient
incub
period
sar
cov
infect
rang
day
may
last
long
day
booth
et
al
lee
et
al
initi
symptom
sar
nonspecif
includ
influenzalik
symptom
fever
chill
rigor
headach
dizzi
malais
myalgia
fever
common
symptom
upon
present
respiratori
phase
sar
begin
day
prodrom
period
booth
et
al
lee
et
al
peiri
et
al
earli
respiratori
stage
sar
includ
dri
nonproduct
cough
mild
dyspnoea
onset
fever
sar
patient
abnorm
chest
radiograph
antonio
et
al
wong
et
al
although
chest
radiograph
may
normal
febril
prodrom
well
throughout
cours
ill
recent
data
toronto
cohort
sar
patient
indic
sar
case
infiltr
end
first
week
ill
patient
never
develop
infiltr
muller
et
al
case
radiolog
evid
pneumon
chang
may
preced
fever
rainer
et
al
particularli
individu
comorbid
may
impair
abil
mount
fever
respons
fisher
et
al
earli
chest
radiograph
sar
often
show
subtl
peripher
pulmonari
infiltr
radiograph
involv
progress
day
becom
bilater
gener
interstiti
confluent
infiltr
airspac
opac
eventu
develop
cours
diseas
patient
deterior
clinic
airspac
opac
may
increas
size
extent
sever
wong
et
al
b
onset
sar
case
may
progress
nonsever
variant
diseas
character
rel
mild
respiratori
symptom
fever
cough
variant
character
persist
intract
cough
christian
et
al
commonli
howev
case
progress
moder
sever
variant
character
develop
dyspnea
hypoxia
day
post
onset
symptom
booth
et
al
lee
et
al
peiri
et
al
recoveri
phase
sar
typic
begin
day
onset
symptom
howev
symptom
may
worsen
hospit
patient
point
mechan
ventil
necessari
booth
et
al
fowler
et
al
lee
et
al
lew
et
al
latter
group
sar
patient
progress
immun
infiltr
lung
diffus
alveolar
damag
unresolv
viral
burden
may
culmin
ard
sever
form
pulmonari
failur
immun
compon
caus
microbi
infect
transplant
reject
prolong
mechan
ventil
trauma
etc
ding
et
al
farca
et
al
hwang
et
al
lew
et
al
saltotellez
et
al
ard
occur
approxim
patient
sar
associ
mortal
rate
context
fowler
et
al
lew
et
al
accord
overal
case
fatal
rate
sar
outbreak
estim
advanc
age
appear
strongest
predictor
poor
outcom
patient
age
year
casefat
rate
number
prognost
factor
identifi
includ
presenc
comorbid
particularli
diabet
mellitu
cardiac
diseas
elev
baselin
ldh
anc
baselin
hypoxemia
extent
radiograph
diseas
given
lack
consensu
therapeut
agent
sar
outbreak
wide
rang
treatment
approach
use
includ
ribavirin
steroid
convalesc
plasma
immunoglobulin
proteas
inhibitor
lopinavir
ritonavir
stockman
et
al
recent
review
therapi
conclud
present
moment
known
potenti
treatment
sar
whether
antivir
immunomodulatori
particularli
effect
event
new
outbreak
stockman
et
al
sar
cov
take
hold
airway
organ
exploit
reninangiotens
pathway
via
main
put
receptor
angiotensinconvert
enzym
express
mani
cell
type
includ
pneumocyt
enterocyt
endotheli
cell
ham
et
al
kuba
et
al
li
et
al
sar
cov
effici
evad
innat
immun
respons
exemplifi
steadili
increas
viral
load
found
host
first
day
sar
infect
wong
et
al
consequ
hyperimmun
inflamm
system
immunopatholog
sar
covinfect
host
well
illustr
lau
peiri
nichol
et
al
wong
et
al
howev
fact
major
sar
patient
recov
rel
moder
diseas
cours
indic
gener
notion
defici
innat
immun
sar
cov
concert
hyperimmun
respons
cytokin
storm
drive
sever
immunopatholog
sar
may
oversimplifi
induct
proinflammatori
cytokin
chemokin
clearli
involv
host
respons
sar
cov
infect
clinic
evolut
diseas
howev
great
deal
controversi
arisen
literatur
regard
relationship
immun
mediat
pathophysiolog
event
sar
earli
work
wong
et
al
demonstr
elev
occur
least
week
onset
sar
high
level
chemokin
associ
acut
sar
infect
wong
et
al
subsequ
studi
tang
et
al
analyz
archiv
plasma
sampl
collect
acut
sar
ill
highlight
increas
level
chemokin
associ
advers
outcom
tang
et
al
focus
elev
plasma
level
associ
immunopatholog
jiang
et
al
show
remain
high
level
sar
patient
convalesc
highli
express
lung
lymphoid
tissu
addit
huang
et
al
found
level
transform
growth
chemokin
patholog
relev
acut
sar
tumor
necrosi
hand
chien
et
al
recent
hypothes
earli
induct
along
subsequ
induct
versu
lack
may
key
develop
sar
immunopatholog
chien
et
al
result
conflict
interpret
data
somewhat
limit
gener
pauciti
clinic
histori
statu
sar
patient
studi
clear
pronounc
express
group
proinflammatori
cytokin
chemokin
associ
acut
case
progress
sar
result
deriv
cohort
clinic
welldefin
sar
patient
n
toronto
sar
outbreak
provid
evid
tempor
involv
cytokin
chemokin
especi
interferon
ifn
ifnstimul
gene
isg
critic
clinic
evolut
sar
suscept
patient
part
larger
global
host
respons
found
sar
symptom
progress
rapidli
patient
acut
infect
fever
peak
median
day
sinc
onset
symptom
dso
chest
radiograph
involv
peak
median
dso
arteri
satur
nadir
occur
median
dso
surviv
patient
nadir
surviv
patient
use
separ
earli
acut
late
phase
sar
patient
requir
mechan
ventil
time
clinic
cours
classifi
sever
sar
sever
sar
patient
exhibit
higher
incid
bilater
lung
infiltr
clinic
cours
diseas
versu
nonsever
sar
patient
sever
sar
patient
also
significantli
older
median
year
old
versu
median
year
old
nonsever
sar
patient
p
significantli
longer
diseas
cours
surviv
versu
nonsever
patient
median
day
sever
sar
patient
versu
median
day
nonsever
patient
p
use
cytometr
bead
array
technolog
manufactur
protocol
bd
bioscienc
nj
usa
found
nonsever
sar
patient
exhibit
significantli
increas
p
level
chemokin
earli
acut
phase
diseas
comparison
healthi
control
level
remain
highli
express
respect
healthi
control
late
phase
tabl
comparison
healthi
control
sever
sar
patient
show
significantli
increas
p
level
along
decreas
level
acut
sar
late
phase
sever
sar
patient
exhibit
significantli
increas
p
level
chemokin
rel
control
decreas
level
cytokin
compar
late
phase
group
sever
sar
patient
exhibit
significantli
higher
p
level
nonsever
patient
hand
sever
group
show
decreas
level
respect
nonsever
group
p
therefor
sar
sever
group
show
increas
level
throughout
diseas
level
sustain
sever
sar
patient
rel
nonsever
late
phase
patient
sever
sar
patient
also
associ
diffus
pulmonari
infiltr
higher
temperatur
longer
period
hospit
data
shown
assembl
comprehens
model
human
immun
system
respond
sar
cov
infect
play
role
pathogenesi
sar
high
research
prioriti
microarray
analysi
gene
express
repres
potenti
valuabl
tool
regard
pauciti
sar
genom
literatur
exist
previou
studi
gener
unabl
assess
human
host
respons
sar
cov
due
insuffici
patient
number
time
point
clinic
inform
platform
coverag
immunerel
gene
nonetheless
yu
et
al
found
inflammatori
gene
particularli
proinflammatori
cytokin
gene
upregul
acut
sar
patient
compar
healthi
control
convalesc
sar
patient
yu
et
al
surprisingli
ifn
express
acut
sar
howev
studi
includ
patient
compar
sarsinfect
patient
healthi
control
reghunathan
et
al
also
found
acut
sar
associ
strong
proinflammatori
gene
respons
albeit
complet
absenc
cytokin
gene
express
reghunathan
et
al
ifnrel
gene
underrepres
studi
lastli
lee
et
al
compar
sar
patient
healthi
control
develop
distinct
gene
signatur
accur
discrimin
sar
patient
nonsar
patient
lee
et
al
primari
goal
studi
howev
develop
gene
signatur
sar
infect
rather
model
host
immun
respons
strive
analyz
innat
adapt
immun
respons
sar
cov
whole
host
level
throughout
natur
histori
sar
use
multipl
techniqu
full
clinic
histori
build
complet
model
possibl
host
immun
inflammatori
respons
ill
bosing
et
al
significantli
deviat
gene
p
involv
ifnrespons
isg
adapt
immun
respons
inflamm
antigen
present
hlamhc
class
ii
immunoglobulin
igl
igh
gene
cluster
chosen
larger
gene
list
identifi
anova
ftest
analysi
earli
n
gene
late
phase
n
gene
sar
patient
versu
healthi
control
n
go
annot
http
wwwgeneontologyorg
interferon
stimul
gene
databas
de
veer
et
al
use
classifi
gene
relat
function
sar
patient
dataset
normal
gene
gene
healthi
control
mean
agglom
hierarch
cluster
pearson
correl
averag
linkag
distanc
metric
use
organ
dataset
correspond
multipl
time
point
onset
symptom
everi
day
throughout
sar
three
repres
patient
describ
text
gene
shown
red
upregul
gene
shown
blue
downregul
rel
healthi
control
end
use
cdna
microarray
sequenc
verifi
est
analyz
host
respons
peripher
blood
mononuclear
cell
toronto
cohort
sar
patient
onset
symptom
discharg
hospit
death
longitudin
anova
ftest
analysi
sar
patient
healthi
control
summar
fig
form
three
repres
patient
sampl
throughout
earli
acut
late
progressionrecoveri
phase
sar
focus
significantli
deviat
gene
p
involv
ifnrespons
isg
adapt
immun
inflamm
antigen
present
human
leukocyt
antigen
hlamajor
histocompat
complex
mhc
immunoglobulin
ig
gene
cluster
gene
hierarch
cluster
multipl
time
point
onset
symptom
everi
day
throughout
clinic
cours
sar
three
repres
patient
fig
patient
exhibit
nonsever
case
sar
recov
day
patient
develop
sever
sar
increas
support
recov
day
patient
also
develop
sever
sar
die
day
shown
fig
isg
cluster
includ
myxoviru
influenza
resist
mxa
peak
express
acut
sar
patient
nonsever
quickli
resolv
end
first
week
sinc
onset
symptom
isg
similarli
upregul
acut
sar
two
sever
patient
howev
mani
gene
includ
receptor
exampl
strongli
express
longer
period
time
unresolv
prior
time
death
patient
isg
profil
echo
express
inflammatori
gene
cluster
includ
exampl
interestingli
evid
grow
adapt
immun
exemplifi
ig
gene
express
increas
express
adapt
immun
respons
cluster
includ
oncogen
three
patient
although
peak
gene
express
adapt
immun
respons
cluster
delay
patient
sever
rel
patient
nonsever
evid
patient
ultim
die
strikingli
nonsever
sar
patient
exhibit
appreci
express
antigen
present
mhc
class
iihla
gene
collect
data
indic
key
signatur
ifn
isg
associ
develop
innat
adapt
immun
respons
clinic
evolut
sar
appear
current
understand
potenti
role
cytokin
chemokin
sar
ie
hypercytokinemia
cytokin
storm
drive
sar
immunopatholog
may
oversimplifi
type
ifn
key
mediat
innat
immun
viral
infect
also
provid
connect
innat
adapt
arm
immun
respons
takaoka
yanai
likewis
sole
type
ii
ifn
critic
contributor
adapt
immun
especi
helper
type
respons
malmgaard
potenti
type
ifn
antivir
activ
takaoka
yanai
contend
ifn
ifnstimul
chemokin
induc
acut
sar
infect
sever
nonsever
patient
part
robust
innat
immun
respons
fig
ifn
respons
may
function
expect
inflammatori
respons
sar
cov
infect
major
sar
patient
recov
nevertheless
unregul
express
ifn
ifnstimul
chemokin
eg
sever
sar
patient
ill
progress
may
lead
widespread
immun
dysregul
seriou
pathogen
event
fig
selfsustain
express
proinflammatori
chemokin
late
sar
suscept
patient
may
compensatori
mechan
incapac
mount
effect
adapt
immun
respons
clear
viru
patient
ultim
succumb
sar
behav
differenti
group
clinic
also
immunolog
point
view
term
sever
acut
respiratori
syndrom
may
fig
model
immunopatholog
event
associ
sar
clinic
evolut
sar
patient
mount
robust
ifnmedi
innat
immun
respons
earli
acut
ill
peak
symptomolog
follow
median
nadir
surviv
patient
late
sar
sar
patient
resolv
inflamm
mount
effect
adapt
immun
sar
cov
immun
dysregul
sever
sar
patient
hallmark
continu
express
inflammatori
chemokin
isg
defici
mhc
ig
gene
express
immunemedi
patholog
worsen
minor
suscept
sar
patient
unresolv
express
viral
burden
associ
poor
outcom
therefor
best
describ
subgroup
particularli
atrisk
patient
character
persist
induct
along
evid
defici
adapt
immun
extens
thorac
involv
sever
compromis
respiratori
indic
viral
evas
sar
infect
may
benefit
part
downregul
type
ifndirect
innat
immun
propos
vitro
studi
castilletti
et
al
cheung
et
al
ziegler
et
al
result
argu
sar
patient
mount
robust
type
ii
ifn
respons
even
express
innat
antivir
isg
mxa
acut
ill
fig
type
ii
ifnrespons
may
therefor
act
maintain
homeostasi
develop
effect
versu
autoinflammatori
innat
adapt
immun
respons
cytokin
chemokin
level
subsid
vast
major
sar
patient
acut
infect
critic
switch
ifndriven
innat
immun
protect
adapt
immun
viral
clearanc
occur
patient
recov
convers
prolong
burden
sar
cov
lung
atrisk
patient
ie
comorbid
describ
may
event
break
homeostat
regul
persist
express
distinct
isg
unremit
induct
protein
level
defici
function
antigen
present
gene
hallmark
patient
progress
hypoxemia
poor
diseas
cours
moreov
defici
express
sever
sar
patient
may
indic
incapac
develop
effect
adapt
immun
respons
patient
ultim
unmanag
viral
load
selfsustain
chemokinemedi
proinflamm
progress
pulmonari
injuryard
characterist
sar
patient
risk
fatal
outcom
fig
host
immun
respons
sar
may
first
map
detail
term
emerg
infecti
diseas
know
exact
mechan
lead
malfunct
switch
innat
adapt
immun
sever
sar
patient
gene
signatur
describ
studi
may
help
assess
immunopatholog
manag
sever
viral
infect
use
genom
technolog
studi
host
respons
sever
viral
ill
sar
avian
influenza
may
identifi
parallel
gene
signatur
diagnost
andor
prognost
clinic
evolut
